Table 3.
Reasons for treatment with Zarzio®: clinician assessment and Zarzio® treatment in patients given primary vs secondary/curative prophylaxis (analysis population, N = 1174)
| Breast (n = 356) | Lung (n = 280) | GI: colorectal (n = 103) | GI: non-colorectal (n = 72) | GYN: ovarian (n = 72) | GYN: non-ovarian (n = 39) | Head & neck (n = 105) | Prostate (n = 66) | Other‡ (n = 81) | Total (N = 1174) | Primary prophylaxis†(n = 772) | Secondary/curative prophylaxis (n = 402) | p value§ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FN risk category according to clinician, n (%) | |||||||||||||
| ≥ 20% | 133 (37.3) | 92 (32.8) | 24 (23.3) | 24 (33.3) | 27 (37.5) | 14 (35.9) | 49 (46.7) | 29 (43.9) | 43 (53.1) | 435 (37.1) | 321 (41.6) | 114 (28.4) | <0.0001 |
| 10–20% with risk factors | 174 (48.9) | 162 (57.9) | 60 (58.3) | 39 (54.2) | 43 (59.7) | 23 (59.0) | 45 (42.8) | 32 (48.5) | 34 (42.0) | 612 (52.1) | 389 (50.4) | 223 (55.5) | |
| < 10% | 49 (13.8) | 26 (9.3) | 19 (18.4) | 9 (12.5) | 2 (2.8) | 2 (5.1) | 11 (10.5) | 5 (7.6) | 4 (4.9) | 127 (10.8) | 62 (8.0) | 65 (16.2) | |
| Reason for G-CSF prescription, n (%)* | |||||||||||||
| Elderly patient | 65 (18.3) | 66 (23.6) | 34 (33.0) | 18 (25.0) | 27 (37.5) | 12 (30.8) | 19 (18.1) | 27 (40.9) | 19 (23.5) | 287 (24.4) | 203 (26.3) | 84 (20.9) | 0.04 |
| Poor functional or nutritional status | 35 (9.8) | 78 (27.9) | 17 (16.5) | 21 (29.2) | 15 (20.8) | 4 (10.3) | 45 (42.9) | 13 (19.7) | 21 (25.9) | 249 (21.2) | 184 (23.8) | 65 (16.2) | <0.01 |
| Low leucocyte levels | 45 (12.6) | 45 (16.1) | 52 (50.5) | 25 (34.7) | 18 (25.0) | 4 (10.3) | 15 (14.3) | 12 (18.2) | 10 (12.3) | 226 (19.3) | 45 (12.6) | 181 (45.0) | <0.0001 |
| Concomitant pathologies | 26 (7.3) | 99 (35.4) | 15 (14.6) | 14 (19.4) | 9 (12.5) | 6 (15.4) | 20 (19.0) | 12 (18.2) | 21 (25.9) | 222 (18.9) | 178 (23.1) | 44 (10.9) | <0.0001 |
| Low haemoglobin levels | 3 (0.8) | 22 (7.9) | 7 (6.8) | 10 (13.9) | 10 (13.9) | 2 (5.1) | 2 (1.9) | 12 (18.2) | 8 (9.9) | 76 (6.5) | 38 (4.9) | 38 (9.5) | <0.01 |
| Prior FN | 19 (5.3) | 13 (4.6) | 3 (2.9) | 4 (5.6) | 9 (12.5) | 0 (0) | 2 (1.9) | 1 (1.5) | 4 (4.9) | 55 (4.7) | 24 (3.1) | 31 (7.7) | <0.001 |
| FN in previous CT cycle | 11 (3.1) | 9 (3.2) | 5 (4.9) | 4 (5.6) | 1 (1.4) | 0 (0) | 1 (1.0) | 1 (1.5) | 5 (6.2) | 37 (3.2) | 7 (0.9) | 30 (7.5) | <0.0001 |
| Prophylactic antibiotic | 0 (0) | 5 (1.8) | 1 (1.0) | 1 (1.4) | 0 (0) | 0 (0) | 1 (1.0) | 1 (1.5) | 0 (0) | 9 (0.8) | 4 (0.5) | 5 (1.2) | 0.29ǁ |
| Other reason** | 219 (61.5) | 106 (37.9) | 31 (30.1) | 23 (31.9) | 31 (43.1) | 20 (51.3) | 40 (38.1) | 33 (50.0) | 37 (45.7) | 540 (46.0) | 391 (50.6) | 149 (37.1) | <0.0001 |
*Multiple reasons could be given
†Primary prophylaxis for FN defined as G-CSF prophylaxis introduced during the first cycle of the current CT regimen.
‡Other ST cohorts include urological outside prostate, sarcoma, thymic carcinoma, skin, bone, unknown primary, multiple independent sites.
§Univariate statistical test
ǁFisher test
**Other reasons for G-CSF prescription include previous CT treatment, toxicity to CT, maintaining dose intensity, neutropenia, heavily pre-treated patients and prophylaxis
CT chemotherapy, FN febrile neutropenia, G-CSF granulocyte colony-stimulating factor, GI gastrointestinal, GYN gynaecological